According to CoinMeta, Eli Lilly ( LLY.N ) announced that the combined therapy of Taltz and Zepbound reached the primary study endpoint at week 36. The response rate of ACR50 with the combination therapy was three times that of using Taltz alone. The study showed that after 1 year of treatment, the response rate for the combined therapy was 43.7%, while the response rate for using Taltz alone was 15.7%.